We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.
Continuing to
Grow & Invest
We are an evergreen fund that has a long-term investment perspective.
Focusing on the
Mid-Atlantic Region
We invest in life-science companies in the Mid-Atlantic region.
Launching Successful
Companies
Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.
Latest News
AllAccelerated BiosciencesAcuity PharmaceuticalsAlleviAlterisAnnovisAtalanAvid RadiopharmaceuticalsBainbridge HealthBioAdvance NewsCeptarisCohero HealthConcarlo TherapeuticsCrossBridgeEliksa TherapeuticsENB TherapeuticsGeneralHalo LabsHanimune TherapeuticsHealthQxHueDxImmunoGenesisImmunomeInfraScanInnervaceIntezyneiView TherapeuticsKaloCyteKayotheraKeritonLatusLumenVuMebias DiscoveryMelior DiscoveryMidway PharmaceuticalsNovira TherapeuticsNuPatheOncora MedicalOnspira TherapeuticsOpsidioOssianixPalvella TherapeuticsPhrase HealthPillo HealthPortfolio NewsProtez PharmaceuticalsPSTRelmada TherapeuticsRenovacorRide HealthSenzoSIRPantStradosThe One Health CompanyTolerance BioTreventis CorporationVenatorx PharmaceuticalsVesteckVittoria BiotherapeuticsWellsheet
IVIEW Therapeutics’ Innovative Gene Therapy GVB-2001 Treats First Primary Open-Angle Glaucoma Patient
IVIEW Therapeutics’ Innovative Gene Therapy GVB-2001 Treats First Primary Open-Angle Glaucoma Patient
Insmed Provides Clinical and Business Update
Insmed Provides Clinical and Business Update
Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module
Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module
ImmunoGenesis Receives $10.8 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Accelerate the Clinical Development of IMGS-001 for Patients with Immune-Excluded Tumors with High Unmet Need